Placental oxidative stress plays a key role in the pathophysiology of placenta-related disorders, most notably preeclampsia (PE) and intrauterine growth restriction (IUGR). Oxidative stress occurs when accumulation of reactive oxygen species (ROS) damages DNA, proteins and lipids, an outcome that is limited by antioxidant enzymes; mitochondrial uncoupling protein 2 (UCP2) may also limit oxidative stress by reducing ROS production. Here we characterized placental antioxidant defenses during normal gestation and following glucocorticoidinduced IUGR. Placentas were collected on Days 16 and 22 of normal rat pregnancy (term ¼ Day 23) and at Day 22 after dexamethasone treatment from Day 13. Expression of several genes encoding antioxidant enzymes (Sod1, Sod2, Sod3, Cat, Gpx3, Txn1, Txnrd1, Txnrd2, and Txnrd3) and Ucp2 was measured by quantitative RT-PCR in the labyrinth (LZ) and junctional zones (JZ) of the placenta. Expression of Sod1 and Ucp2 mRNAs and the activity of xanthine oxidase, a source of ROS, all increased from Days 16 to 22 in both placental zones, whereas Sod2 and Gpx3 increased only in the rapidly growing LZ. In contrast, Sod3 and Txnrd1 expression fell in the LZ over this period, whereas total superoxide dismutase activity remained stable. Dexamethasone treatment reduced fetalplacental growth and LZ expression of Ucp2 but increased JZ expression of Txn1. Indices of placental oxidative damage (TBARS, F 2 -isoprostanes, and 8-OHdG) did not change with gestational age or dexamethasone, indicative of adequate antioxidant protection. Overall, our data suggest that the rat placenta is protected from oxidative stress by the dynamic zoneand stage-dependent expression of antioxidant defense genes.
INTRODUCTION
Placenta-related disorders including miscarriage, preeclampsia (PE) and intrauterine growth retardation (IUGR) affect around a third of all human pregnancies [1] . There is now considerable evidence that oxidative and nitrative stress within uteroplacental tissues plays a pivotal role in the development of these pathologies [1] [2] [3] . Oxidative stress occurs when cellular production of reactive oxygen species (ROS), including that associated with normal oxidative metabolism, outweighs the protective capacity of antioxidant defenses. Intracellular ROS are produced in mitochondria as a by-product of normal cellular metabolism and in the cytoplasm via xanthine oxidase (XO) and NAD(P)H oxidase activities [4, 5] . While ROS function as important cell signaling molecules, excess ROS cause damage to cellular lipids, proteins, and DNA, including effects mediated via peroxynitrite formed from superoxide and nitric oxide (i.e., nitrative stress) [3] . ROS accumulation is limited by a range of antioxidant enzymes, including the superoxide dismutases (SODs), which catalyze conversion of superoxide to hydrogen peroxide (H 2 O 2 ), and oxygen, while H 2 O 2 is inactivated by catalase (CAT), glutathione peroxidase (GPX), and the thioredoxin system [4, 5] . In addition to these antioxidant enzymes, ROS production may be limited by the uncoupling proteins (UCPs), which appear to limit oxidative damage in other tissues. For example, Ucp2-null mice show increased ROS production in several cell types including macrophages [6] and adipocytes [7] , indicative of a role for UCP2 in reducing ROS production. It is unknown, however, if UCP2 plays a similar role in placental tissue or is disturbed in human placental pathologies. Importantly, Ucp2 gene expression has been shown to increase in sheep placenta with advancing gestation and is responsive to altered nutritional status [8, 9] .
The placenta appears particularly vulnerable to oxidative stress because of its extensive cell division and high metabolic activity [1, 4] . The early stages of human embryonic development take place in a low oxygen environment [4] which is thought to limit ROS generation [10] , but as the placenta becomes increasingly oxygenated late in the first trimester, an increase in antioxidant capacity occurs. Thus, in human pregnancy, antioxidant enzyme mRNA expression (CAT, GPX, and SODs) [10] and antioxidant enzyme activity (CAT and SOD) [10, 11] both rise late in the first trimester. Less is known about subsequent changes in placental antioxidant gene expression later in pregnancy when fetal growth is maximal, although Takehara et al. [11] have reported further increases in CAT and SOD activities toward term. In rodents, the physiological impact of antioxidant defenses on fetal growth was recently highlighted by two separate studies. Firstly, global overexpression of thioredoxin 1 (Txn1) was shown to reduce placental oxidative stress and enhance fetal growth [12] , and in a rat model of undernutrition, fetal growth retardation was prevented by melatonin treatment, an effect associated with enhanced antioxidant protection in the placenta [13] . Despite this importance, little is known of the spatial and temporal patterns of placental antioxidant gene expression in normal rodent pregnancy.
In this study we tested the hypothesis that placental expression of the major antioxidant defense genes increase during the final third of pregnancy in rats, particularly in the labyrinth zone (LZ), the site of fetal-maternal exchange. Rapid growth of the LZ in late gestation is accompanied by 4-fold increase in its maternal vascular volume [14] and a dramatic rise in placental blood flow [15] . This suggests that the LZ is likely to require greater antioxidant protection than the adjacent junctional zone (JZ) in late gestation. Therefore, we measured expression of a range of antioxidant defense genes (Sod1, Sod2, Sod3, Cat, Gpx3, Txn1, Txnrd1, Txnrd2, Txnrd3, and Ucp2) and activities of total SOD and XO in the placental LZ and JZ at Days 16 and 22 of pregnancy (term ¼ Day 23). Placental oxidative damage was assessed by measurement of F 2 -isoprostanes and thiobarbituric acid reactive substances (TBARS), both measures of lipid peroxidation, and 8-hydroxy-2-deoxy-guanosine (8-OHdG), indicative of oxidative damage to DNA. We also assessed whether placental antioxidant defenses were compromised in a model of glucocorticoidinduced IUGR since glucocorticoids are known to increase ROS generation in other tissues [16, 17] and increased placental glucocorticoid exposure occurs in both PE [18] and IUGR [19] .
MATERIALS AND METHODS

Animals
Nulliparous albino Wistar rats, 8-12 wk old, were obtained from the Animal Resources Centre (Murdoch, Australia) and maintained under controlled conditions as described previously [20] . Rats were mated overnight, with Day 1 of pregnancy designated as the day on which spermatozoa were present in a vaginal smear. Mothers were treated with dexamethasone acetate (1 lg/ml drinking water; Sigma, St. Louis, MO) from Days 13 to 22 of pregnancy, previously shown to consistently restrict fetal and placental growth [14] . This approach also avoids the need for sham injections in control mothers, which was recently shown to increase endogenous glucocorticoid secretion [21] . All procedures involving animals were conducted after approval by the Animal Ethics Committee of The University of Western Australia.
Tissue Collection
Rats were anesthetized with isofluorane/nitrous oxide at either Day 16 or Day 22 of gestation. Three fetus-placenta pairs were obtained from the midregion of each uterine horn (total of six per mother) and weighed. Each placenta was then dissected into junctional and labyrinth zones, which were weighed individually and snap frozen in liquid nitrogen. Measurement of genes that are differentially expressed between placental zones confirms adequate separation by this method [20] . One junctional-labyrinth pair from each pregnancy was used for all mRNA, enzyme activity, and oxidative damage analyses.
RNA Sample Preparation
Total RNA was isolated from placental zones using Tri-Reagent (Molecular Resources Centre, Cincinnati, OH) as per the manufacturer's instructions. Total RNA (1 lg) was used as a template for cDNA synethsis by M-MLV Reverse Transcriptase RNase H Point Mutant and random hexamer primers (Promega, Madison, WI) as per the manufacturer's instructions. The resultant cDNAs were purified using the Ultraclean PCR Cleanup kit (MoBio Industries, Solana Beach, CA).
Real-Time RT-PCR
Analyses of mRNA expression levels for Sod1, Sod2, Sod3, Cat, Gpx3, Txn1, Txnrd1, Txnrd2, Txnrd3, Ucp2, and the housekeeping gene Rpl19 were performed by real time RT-PCR on the Rotorgene 6000 (Corbett Industries, Sydney, Australia) using 0.2 lM of primers, SYBR Green (Molecular Probes, Eugene, OR) at 1/40 000 of stock, and 0.5 U of Immolase DNA polymerase (Bioline, Alexandria, Australia) per reaction. Primer pairs for all genes of interest (Table 1) were designed using Primer 3 software (MIT/Whitehead Institute, Cambridge, MA; http://www-genome.wi.mit.edu) [22] except for Rpl19 [23] . Each of the selected primer pairs were positioned to span introns to ensure that no product was amplified from genomic DNA, and the resulting amplicons were sequenced to confirm specificity (data not shown). All samples were standardized against Rpl19 as previously described [23] . Standard curves for each amplicon were generated with 10-fold serial dilutions of gel-extracted (QIAEX II; Qiagen, Melbourne, Australia) PCR products using the Rotorgene 6000 software.
Placental SOD and XO Enzyme Activities
Activities of SOD and XO were measured in placental zone homogenates by commercial assay kits (Cayman Chemical Company, Ann Arbor, MI). LZ and JZ tissues (approximately 40 mg of each) were homogenized using the POLYTRON-Aggregate (Kinematica, Lucerne, Switzerland). For the SOD ANTIOXIDANT DEFENSES IN RAT PLACENTA activity assay, tissues were homogenized in 10 vol of 20 mM HEPES buffer (pH 7.2, containing 1 mM EGTA, 210 mM mannitol, and 70 mM sucrose). Samples were centrifuged at 1500 3 g for 5 min at 48C, and the cell lysate supernatant was stored at À808C until protein quantification by Bradford assay. The SOD activity assay was performed as per manufacturer's instructions and read at 440 nm on the Labsystems Multiskan plate reader (Labsystems, Finland). Values for SOD activity were expressed as mU per mg protein. For the XO activity assay, tissues were homogenized in 10 vol of cold buffer (100 mM Tris-HCl, pH 7.5, with protease inhibitor cocktail P8340; Sigma) and then centrifuged at 10 000 3 g for 15 min at 48C. The cell lysate supernatant was stored at À808C until protein quantification by Bradford assay. The XO activity assay was performed as per the manufacturer's instructions, with fluorescence read at an excitation wavelength of 544 nm and an emission wavelength of 590 nm on the Fluostar OPTIMA plate reader (BMG Labtech, Mornington, Australia). Values for XO activity were expressed as U per mg protein.
Measurement of F 2 -Isoprostanes
LZ tissue (;50 mg) was ground to a fine powder with a porcelain mortar and pestle chilled with liquid nitrogen. F 2 -isoprostanes were extracted then measured in duplicate by gas chromatography-mass spectrometry (GC-MS) using electron capture chemical ionization as previously reported [24] .
Measurement of Thiobarbituric Acid Reactive Substances
Levels of thiobarbituric acid reactive substances (TBARS) in placental zones was measured by a commercial assay kit (Cayman Chemical). Tissues (25-50 mg) were first sonicated in 250 ll of RIPA buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 % Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mM PMSF) with protease inhibitors (P8340; Sigma) for 15 sec at 40 V. Samples were then centrifuged at 1600 3 g for 10 min at 48C. The TBARS assay was performed in duplicate as per the manufacturer's instructions, and resultant absorbances were read at 540 nm on the Labsystems Multiskan plate reader.
Measurement of 8-Hydroxy-2-Deoxy-Guanosine
Levels of 8-hydroxy-2-deoxy-guanosine (8-OHdG) in placental zones were measured by a commercial assay kit (Cayman Chemical). Initially, genomic DNA was extracted (Promega DNA Extraction kit), and 8 lg were exposed sequentially to nuclease P1 enzyme (Sigma) and alkaline phosphatase from bovine kidney (Sigma) according to the manufacturer's protocols. The 8-OHdG assay was then performed in duplicate as per the manufacturer's instructions, and resultant absorbances were read at 405 nm on the Labsystems Multiskan plate reader.
Statistical Analysis
All values are expressed as the mean 6 SEM. Fetal, total placental and placental zone weight values for each pregnancy were calculated as the average of the six estimates of each. Variations in enzyme activities and mRNAs encoding antioxidant enzymes and Ucp2 were assessed by two-way ANOVAs (Genstat version 9, VSN International Ltd., Hemel Hempstead, UK), with variation attributed to placental zone and either gestational age or dexamethasone treatment. Where the F-test reached statistical significance (P , 0.05), 
Values are the mean 6 SEM (n ¼ 6 per group). *P , 0.05, **P , 0.01, compared to corresponding Day 16 value; P , 0.01 overall zone effect (two-way ANOVA and least significant difference test).
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pairwise comparisons were made by least significant difference tests [25] . When there was significant interaction between sources of variation, separate comparisons were made by unpaired t-tests. Differences in F 2 -isoprostane and TBARS concentrations were assessed by unpaired t-tests. Because the majority of data were not normally distributed (based on residuals plot analyses), values were log transformed prior to statistical analyses.
RESULTS
Fetal and Placental Weight Changes
Consistent with our previous reports [20, 26] , fetal and placental weights increased markedly from Day 16 to 22 of pregnancy (fetus: 18-fold increase, P , 0.001; placenta: 2-fold, P , 0.001; see Table 2 ). The increase in placental weight was due predominantly to LZ growth (3.3-fold increase, P , 0.001), with no significant change in JZ weight. Dexamethasone treatment from Day 13 reduced fetal weight at Day 22 (24%; P , 0.001) and placental weight by 36%, attributable to both LZ (42%; P , 0.001) and JZ (34%; P , 0.01) growth retardation (see Table 2 ).
Placental Antioxidant Gene Expression
Labyrinth zone. Sod1, Sod2, and Gpx3 mRNA expression (Fig. 1, A and B , and 2A) all increased in the LZ from Day 16 to Day 22 (20%, P , 0.05; 70%, P , 0.01 and 62%, P , 0.05, respectively). Conversely, Sod3 expression decreased by 42% (P , 0.01) and Txnrd1 by 51% (P , 0.05) (Figs. 1C and 2B) . Expression of Cat (Fig. 1D) , Txnrd2 (Fig. 2C) , Txnrd3 (Fig.  2D) , and Txn1 (Fig. 3A) mRNAs did not vary with gestational age in this placental zone, whereas Ucp2 expression (Fig. 4A) increased 2-fold (P , 0.001). Maternal dexamethasone treatment reduced placental Ucp2 mRNA expression in the LZ (44%; P , 0.05) (Fig. 4B ) but did not affect expression of any of the antioxidant enzymes (data not shown).
Junctional zone. Sod1 mRNA expression (Fig. 1A ) increased in the JZ from Days 16 to 22 (40% increase; P , 0.05). In contrast, Sod3 expression (Fig. 1C ) decreased by 60% (P ¼ 0.01) in this zone, whereas that of Sod2 (Fig. 1B) , Cat (Fig. 1D) , Gpx3 ( Fig. 2A) , Txnrd1 (Fig. 2B) , Txnrd2 (Fig. 2C) , Txnrd3 (Fig. 2D) , and Txn1 (Fig. 3A) remained unchanged. JZ expression of Ucp2 mRNA (Fig. 4A) increased by 3.2-fold from Day 16 to 22 (P , 0.001). Maternal dexamethasone treatment increased Txn1 mRNA expression 2-fold (P , 0.05) but had no effect on expression of any of the other genes (data not shown).
Placental SOD and XO Enzyme Activities
Total SOD activity was similar in the LZ and JZ at Day 16 (109 6 16 and 120 6 17 U/mg protein, respectively) and did not change with gestational age (Day 22: 119 6 23 and 115 6 14, respectively) or dexamethasone treatment (LZ: 96 6 14; JZ: 123 6 10). XO activity was higher in JZ than in LZ at both stages of pregnancy (overall zone effect P , 0.001, ANOVA) and increased in both zones between Days 16 and 22 (overall gestational age effect P , 0.001, ANOVA) (Fig. 5A) . Proportionally, the rise in XO activity over this period was much greater in the LZ (14-fold increase) than in the JZ (75% increase). Dexamethasone treatment had no effect on XO activity at Day 22 (Fig. 5B) . Values are the mean 6 SEM (n ¼ 6 per group). *P , 0.05 compared to corresponding Day 16 value; P , 0.01 overall zone effect (two-way ANOVA and least significant difference test).
Markers of Placental Oxidative Stress
Indices of lipid peroxidation (TBARS and F 2 -isoprostanes) and DNA damage (8-OHdG) were all readily detectable in placental tissues, but none varied significantly with placental zone or gestational age (overall means, TBARS: 1.2 6 0.2 lmol/mg protein; F 2 -isoprostanes: 1.09 6 0.12 ng/g tissue; 8-OHdG: 739 6 53 pg/lg DNA). Maternal dexamethasone treatment had no effect on the levels of TBARS, F 2 -isoprostanes or 8-OHdG (results not shown).
DISCUSSION
There is mounting evidence that oxidative stress in uteroplacental tissues plays a pivotal role in the development of pregnancy complications, including PE and idiopathic IUGR, yet the control of placental ROS accumulation remains poorly understood. The aim of this study was to characterize the antioxidant defense mechanisms of the rat placenta over the final third of pregnancy and to determine whether these mechanisms respond to or are compromised by excess glucocorticoid exposure. The major findings were that expression of Sod1, Sod2, Gpx3, and Ucp2 all increased in the rapidly growing LZ towards term, and Sod1 and Ucp2 also increased in the JZ. These changes in antioxidant enzyme expression were accompanied by increased xanthine oxidase activity, especially in the LZ. In contrast, Sod3 mRNA expression fell markedly in both LZ and JZ, as did that of Txnrd1 in the LZ. Maternal dexamethasone treatment reduced LZ expression of Ucp2, an effect likely to increase ROS production, but importantly there was no evidence of increased Dex; B) . Values are the mean 6 SEM (n ¼ 6 per group). *P , 0.05 compared to corresponding Con value; **P , 0.001 compared with corresponding Day 16 value; P , 0.01 overall zone effect (two-way ANOVA and least significant difference test). Dex; B) . Values are the mean 6 SEM (n ¼ 6 per group). *P , 0.01 compared to corresponding control value (twoway ANOVA and least significant difference test).
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placental oxidative damage following this treatment. Collectively, our data demonstrate a highly dynamic and zonespecific pattern of placental antioxidant gene expression that is consistent with a role in limiting oxidative damage in late gestation and is largely unaffected in a model of glucocorticoid-induced IUGR.
The rapid growth of the fetus between Days 16 and 22 of rat pregnancy is supported by marked growth of the LZ, the site of maternal-fetal exchange, whereas the size of the adjacent JZ remains relatively stable. Previous studies show that growth of the LZ is accompanied by large increases in vascularization [14] and blood flow [15] , changes that facilitate nutrient/ oxygen delivery and thus increased metabolic activity [27] . These changes, together with our observation of increased xanthine oxidase activity in both zones (14-fold in the LZ), suggest that placental ROS generation increases in late gestation. Despite this, all three indices of oxidative damage (i.e., F 2 isoprostanes, TBARS, and 8-OHdG) remained unchanged in both placental zones between Days 16 and 22, indicative of adequate antioxidant protection. Accordingly, we show that LZ expression of Sod1, Sod2, Gpx3, and Ucp2 all increased near term, as did JZ expression of Sod1 and Ucp2. This increased antioxidant protection during the period of maximal fetal growth is consistent with the reported rise in placental SOD and catalase enzyme activities over the course of human pregnancy [11] .
The rise in placental Sod1 and Sod2 mRNA expression between Days 16 and 22 was not paralleled by an increase in total SOD activity, which remained stable in both placental zones. This may be due to the concomitant reduction in Sod3 gene expression (both zones), although this explanation is complicated by the fact that Sod3 encodes a secreted version of the enzyme. Therefore, it is uncertain whether its activity in homogenized placental tissue in vitro accurately reflects that within the placenta in vivo. Clearly, further studies on the relative contributions of the three Sod isoforms are necessary to clarify their relative contributions to superoxide conversion to H 2 O 2 within placenta. The subsequent step of H 2 O 2 inactivation is even more complex, with potential contributions from catalase, glutathione peroxidase, and the thioredoxin system. Among these antioxidants, expression of Cat, Txn1, Txnrd2, and Txnrd3 mRNAs were all maintained in both placental zones over late gestation, whereas LZ expression of Gpx3 increased slightly, and that of Txnrd1 decreased. Further studies on the activity of each of these antioxidant enzymes are required to determine their relative importance, but studies in mice suggest that Txn1 may be a particularly important player. Thus, global overexpression of this antioxidant was recently shown to reduce placental oxidative damage and enhance fetal growth by more than 20% [12] . This suggests that in normal rodent pregnancy, H 2 O 2 scavenging capacity limits placental function and thus fetal growth, either directly or indirectly via other organs. In any event, and regardless of the specific contributions of Txn1 and the other H 2 O 2 scavenging enzymes, the capacity of the placenta to inactivate H 2 O 2 at Day 22 was sufficient to protect against oxidative damage since no increase in F 2 isoprostanes, TBARS, or 8-OHdG was observed.
Maternal dexamethasone treatment was used as a model of glucocorticoid-induced IUGR. The impact of glucocorticoid excess on placental oxidative stress is of particular interest since previous studies show that dexamethasone increases plasma F 2 -isoprostane concentrations in nonpregnant rats [28] . Moreover, in pregnancy pathologies characterized by increased placental oxidative stress (i.e., PE and IUGR), placental glucocorticoid exposure is thought to be elevated because of lower 11b-hydroxysteroid dehydrogenase type 2 expression [18, 19] . In the present study, however, we found no evidence of increased placental oxidative damage after dexamethasone treatment (i.e., no change in F 2 isoprostanes, TBARS, or 8-OHdG) despite profound effects on placental and fetal growth and a marked reduction in LZ expression of Ucp2. Previous studies have established an important role for Ucp2 in limiting oxidative damage in other tissues, with Ucp2-null mice showing increased ROS production in several cell types, including macrophages [6] and adipocytes [7] . Whether Ucp2 plays a similar role in placental tissue or is disturbed in human placental pathologies remains to be established. Our observation that dexamethasone reduced Ucp2 expression in LZ is the first evidence for glucocorticoid inhibition of Ucp2 in vivo and is consistent with similar effects observed in bovine mammary epithelial cell cultures [29] . The normal increase in placental Ucp2 expression observed in both JZ and LZ with advancing gestation is similar to reports in sheep pregnancy [8, 9] . While these increases may serve to enhance antioxidant protection in the late gestation placenta, they are also likely to impact on placental nutrient metabolism, especially at times of increased energy demand [9] . Other than reduced Ucp2 expression, the only observed effect of dexamethasone treatment, other than fetal-placental growth Values are the mean 6 SEM (n ¼ 6 per group). *P , 0.01 overall gestational age effect; P , 0.01, P , 0.001 overall zone effect (twoway ANOVA and least significant difference test).
retardation, was increased JZ expression of Txn1, possibly a compensatory response to higher ROS production.
There were several notable differences in antioxidant gene expression between the two placental zones. Although both are trophopblastic in origin and are perfused by maternal blood, only the LZ has a fetal vasculature and thus is the site of maternal-fetal exchange. Expression of Sod3, Cat, and Txnrd2 were all consistently higher in the LZ, possibly indicative of a greater antioxidant capacity to cope with this zone's higher metabolic activity in late gestation. In contrast, Gpx3 and Txnrd3 were higher in the JZ, which may simply reflect different strategies of antioxidant protection in the two zones. Notably, in addition to their other independent functions, CAT, GPX, and the thioredoxin system all catalyze conversion of H 2 O 2 to water, and so there is likely to be a degree of redundancy among these enzymes. In relation to ROS production within the placenta, it is of interest that XO activity was consistently higher in JZ than LZ, possibly reflecting a more important signaling role for ROS in JZ at this stage of pregnancy. Indeed, ROS are known to provide a potent stimulus to apoptotic signaling [5] , and we have previously shown that apoptosis occurs at a higher rate in JZ compared to LZ near term [26] . Finally, XO activity increased in both placental zones toward term, particularly in the LZ (14-fold increase), suggesting that this enzyme system could add a significant additional ROS burden within the term placenta. Moreover, these data suggest that XO activity is highly regulated in late gestation, consistent with a recent report showing that total placental XO activity is reduced by melatonin treatment [13] .
In conclusion, this study demonstrates that the rat placenta has highly dynamic and zone-specific patterns of antioxidant gene expression over the final third of gestation. These patterns of expression are consistent with antioxidant genes playing an important role in limiting oxidative damage at a time when placental vascular adaptations facilitate large increases in oxygen delivery and utilization.
